Vor BiopharmaVOR
VOR
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Employees: 168
0
Funds holding %
of 7,345 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $28K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
13% less funds holding
Funds holding: 52 [Q4 2024] → 45 (-7) [Q1 2025]
36% less capital invested
Capital invested by funds: $67.6M [Q4 2024] → $43.1M (-$24.5M) [Q1 2025]
40.62% less ownership
Funds ownership: 88.75% [Q4 2024] → 48.13% (-40.62%) [Q1 2025]
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.40
81%
downside
Avg. target
$1.47
29%
downside
High target
$3
46%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 46%upside $3 | Buy Reiterated | 14 Aug 2025 |
Baird Jack Allen | 51%downside $1 | Neutral Maintained | 27 Jun 2025 |
Wedbush David Nierengarten | 81%downside $0.40 | Neutral Reiterated | 26 Jun 2025 |
Financial journalist opinion
Based on 6 articles about VOR published over the past 30 days
Positive
Benzinga
1 day ago
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.
Neutral
GlobeNewsWire
2 days ago
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren's disease.
Neutral
GlobeNewsWire
1 week ago
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities
Neutral
GlobeNewsWire
3 weeks ago
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development
Neutral
GlobeNewsWire
3 weeks ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company's Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Neutral
GlobeNewsWire
4 weeks ago
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Neutral
GlobeNewsWire
1 month ago
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025.
Neutral
GlobeNewsWire
1 month ago
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company's Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio's common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Positive
Benzinga
1 month ago
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market
H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept.
Positive
Zacks Investment Research
1 month ago
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Charts implemented using Lightweight Charts™